Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Keros Therapeutics, Inc. shareholders approved Ratification of the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-06 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-06
Exact text from the filing
Proposal 2 – Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2023 The Company’s stockholders approved Proposal 2. The votes cast were as follows: Votes For Votes Against Votes Abstain 26,790,800 2,224 1 There were no broker non-votes with respect to Proposal 2.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Keros Therapeutics, Inc. shareholders approved Election of two nominees for director to hold office until the Company’s 2026 Annual Meeting of Stockholders at the 2023-06-06 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-06
Exact text from the filing
Proposal 1 – Election of Directors The Company’s stockholders elected the two persons listed below as directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The votes cast were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Carl L. Gordon 11,486,998 13,409,802 1,896,225 Tomer Kariv 19,234,712 5,662,088 1,896,225
View on SEC.gov